Precision Psychiatry: Exploring the Clinical Utility of Pharmacogenetic Testing
Presented by Muneer Ali, D.O.
Recorded on Friday, March 15th, 2024
Access provided upon registration on “My Courses” page
In this presentation Dr. Muneer Ali will provide an overview of pharmacogenetic (PGx) testing in Psychiatry and its potential benefits. He will cover the history and progression of PGx, and explore studies demonstrating improved medication selection and efficacy, as well as a reduction of adverse drug reactions and side effects. Dr. Ali will then discuss practical considerations for integrating pharmacogenetic testing in clinical practice, address potential challenges and limitations, and cover the importance of a multidisciplinary approach to patient care. Lastly, he will highlight how increasing patient engagement with this personalized medicine approach can help enhance treatment adherence, patient satisfaction, and ultimately the patient-provider therapeutic alliance.
When attended in full, this program offers 1.0 APA CEs for Psychologists.
In this presentation Dr. Muneer Ali will provide an overview of pharmacogenetic (PGx) testing in Psychiatry and its potential benefits. He will cover the history and progression of PGx, and explore studies demonstrating improved medication selection and efficacy, as well as a reduction of adverse drug reactions and side effects. Dr. Ali will then discuss practical considerations for integrating pharmacogenetic testing in clinical practice, address potential challenges and limitations, and cover the importance of a multidisciplinary approach to patient care. Lastly, he will highlight how increasing patient engagement with this personalized medicine approach can help enhance treatment adherence, patient satisfaction, and ultimately the patient-provider therapeutic alliance.
After attending this introductory-level program, participants will be able to:
- Describe the status of pharmacogenetics testing in Psychiatry and it’s current role in clinical practice.
- List several key statistics regarding efficacy of PGx testing from the most recent research.
- Explain important factors related to implementing PGx in clinical practice, including advances in integration as well as challenges and limitations.
This program meets APA’s continuing education STANDARD 1.1: Program content focuses on application of psychological assessment and/or intervention methods that have overall consistent and credible empirical support in the contemporary peer reviewed scientific literature beyond those publications and other types of communications devoted primarily to the promotion of the approach.
This program meets APA’s continuing education GOAL 3: Program will allow psychologists to maintain, develop, and increase competencies in order to improve services to the public and enhance contributions to the profession.
Muneer Ali, D.O.; Practicing Child, Adolescent and Adult Psychiatrist; Senior Director of Medical Affairs, Neuropsychiatry, Tempus AI
Dr. Ali is a double board-certified child, adolescent and adult psychiatrist specializing in advanced diagnostics and therapeutics for psychiatric disorders. He takes a special interest in the clinical use of pharmacogenomics in psychiatry and serves as senior director of medical affairs in the neuropsychiatry division of Tempus AI. In this role, Dr. Ali aspires to advance the field through the application of machine learning to big data, and the development of AI-driven decision support tools for clinicians.
In his clinical work, Dr. Ali takes a whole person approach to understand his patients and enjoys working with all age ranges, taking a particular interest in ADHD, anxiety disorders, and PTSD. Dr. Ali completed his training in Psychiatry at the State University of New York, followed by a Fellowship in Child and Adolescent Psychiatry where he served as Chief Fellow in his final year.
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007). The STAR*D Project results: a comprehensive review of findings. Current psychiatry reports, 9(6), 449–459. https://doi.org/10.1007/s11920-007-0061-3
Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 [published correction appears in Pharmacopsychiatry. 2018 Jan;51(1-02):e1]. Pharmacopsychiatry. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492
Koopmans AB, Braakman MH, Vinkers DJ, Hoek HW, van Harten PN. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry. 2021;11(1):141. Published 2021 Feb 24. doi:10.1038/s41398-02001129-1
Fan, M., & Bousman, C. A. (2020). Estimating the Potential Impact of CYP2C19 and CYP2D6 Genetic Testing on Protocol-Based Care for Depression in Canada and the United States. Molecular neuropsychiatry, 5(Suppl 1), 27–33. https://doi.org/10.1159/000504253
Oslin, D. W., Lynch, K. G., Shih, M. C., Ingram, E. P., Wray, L. O., Chapman, S. R., Kranzler, H. R., Gelernter, J., Pyne, J. M., Stone, A., DuVall, S. L., Lehmann, L. S., Thase, M. E., PRIME Care Research Group, Aslam, M., Batki, S. L., Bjork, J. M., Blow, F. C., Brenner, L. A., Chen, P., … Wood, A. E. (2022). Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA, 328(2), 151–161. https://doi.org/10.1001/jama.2022.9805
Arnone, D., Omar, O., Arora, T., Östlundh, L., Ramaraj, R., Javaid, S., Govender, R. D., Ali, B. R., Patrinos, G. P., Young, A. H., & Stip, E. (2023). Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. Neuroscience and biobehavioral reviews, 144, 104965. https://doi.org/10.1016/j.neubiorev.2022.104965
Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R. L., Chiulli, D. L., LLerena, A., Skaar, T. C., Scott, S. A., Stingl, J. C., Klein, T. E., Caudle, K. E., Gaedigk, A., & Clinical Pharmacogenetics Implementation Consortium (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical pharmacology and therapeutics, 98(2), 127–134. https://doi.org/10.1002/cpt.147
Blazy, C., Ellingrod, V., & Ward, K. (2022). Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics. Frontiers in pharmacology, 13, 939313. https://doi.org/10.3389/fphar.2022.939313
Target Audience: Psychologists.
Psychologists. This program, when attended in its entirety, is available for 1.0 continuing education credits. The Chicago School of Professional Psychology is committed to accessibility and non-discrimination in its continuing education activities. The Chicago School of Professional Psychology is also committed to conducting all activities in conformity with the American Psychological Association’s Ethical Principles for Psychologists. Participants are asked to be aware of the need for privacy and confidentiality throughout the program. If program content becomes stressful, participants are encouraged to process these feelings during discussion periods.
Non Psychologists. Most licensing boards accept Continuing Education Credits sponsored by the American Psychological Association but non-psychologists are recommended to consult with their specific state-licensing board to ensure that APA-sponsored CE is acceptable.
*Participants must attend 100% of the program in order to obtain a Certificate of Attendance.
If participants have special needs, we will attempt to accommodate them. Please address questions, concerns and any complaints to [email protected]. There is no commercial support for this program nor are there any relationships between the CE Sponsor, presenting organization, presenter, program content, research, grants, or other funding that could reasonably be construed as conflicts of interest.